pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili S.r.l.
Istituto Gentili Italia trial registry — 50 ClinicalTrials.gov studies with program phase, status, and indication context.
Registry index of 50 ClinicalTrials.gov studies linked to Istituto Gentili Italia programs — each row shows trial ID, program name, phase, status, and indication.
Istituto Gentili Italia trial registry — 50 ClinicalTrials.gov studies with program phase, status, and indication context.
Latest clinical program signals indexed for Istituto Gentili Italia.
RC 4/24 TREAT-UTI — Phase 3
PRINCE — Phase 3
IRST100.59 — Phase 2
5MILLE_CT1 — Phase 2
Wegovy solution for Diabetes Mellitus, Cardiovascul… — Phase 3
CYCLOPHOSPHAMIDE for Inoperable locally advanced or… — Phase 2
PLACEBO for amyotrophic lateral sclerosis — Phase 3
KEYTRUDA for Locally recurrent, inoperable… — Phase 2
Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall
Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.
metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)
Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens
Primary Membranous Nephropathy
Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.
patients scheduled to undergo elective surgical procedures with general anesthesia
Patients with breast lesions undergoing further examination
relapsing vulvar carcinoma already subjected to multiple treatments
oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT
Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.
patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome
Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.
NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs
Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)